Engineered anti-TSLP antibody
View Patent ↗The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.
1. A binding compound that specifically binds human TSLP comprising:
an antibody heavy chain variable region or a TSLP-binding fragment thereof, said heavy chain variable region comprising: a CDR-H1 sequence comprising SEQ ID NO:1, a CDR-H2 sequence comprising SEQ ID NO:2, and a CDR-H3 sequence comprising SEQ ID NO:3; and
an antibody light chain variable region or a TSLP-binding fragment thereof, said light chain variable region comprising: a CDR-L1 sequence comprising SEQ ID NO:4, a CDR-L2 sequence comprising SEQ ID NO:5, and a CDR-L3 sequence comprising SEQ ID NO:6.
2. The binding compound of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7.
3. The binding compound of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:8.
4. The binding compound of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:8.
5. The binding compound of claim 1 , wherein the binding compound is an antibody comprising SEQ ID NO:11 and SEQ ID NO:12.
6. The binding compound of claim 1 , wherein the binding compound can be expressed from the vector deposited under ATCC Deposit No. PTA-10482.
7. The binding compound of claim 1 , wherein the binding compound is a humanized antibody or a TSLP-binding fragment thereof.
8. The binding compound of claim 1 , wherein the binding compound is a TSLP-binding antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
9. A composition comprising the binding compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.
10. An isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof that specifically binds human TSLP, wherein the heavy chain variable region of the antibody comprises a CDR-H1 sequence comprising SEQ ID NO:1, a CDR-H2 sequence comprising SEQ ID NO:2, and a CDR-H3 sequence comprising SEQ ID NO:3; and
the light chain variable region of the antibody comprises a CDR-L1 sequence comprising SEQ ID NO:4, a CDR-L2 sequence comprising SEQ ID NO:5, and a CDR-L3 sequence comprising SEQ ID NO:6.
11. An expression vector comprising the nucleic acid of claim 10 .
12. An isolated host cell comprising the expression vector of claim 11 .
13. A method of producing an antibody encoded by the nucleic acid of claim 10 comprising:
culturing a host cell transformed with an expression vector comprising said nucleic acid under conditions wherein the nucleic acid is expressed thereby producing said antibody; and recovering said antibody from the host cell or culture medium.
14. The expression vector deposited under ATCC Deposit No. PTA-10482.
15. An isolated host cell comprising the expression vector of claim 14 .